Gabrielle J. Halpern
Tel Aviv University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gabrielle J. Halpern.
American Journal of Human Genetics | 2001
Hagit Toledano-Alhadef; Lina Basel-Vanagaite; Nurit Magal; Bella Davidov; Sophie Ehrlich; Valerie Drasinover; Ellen Taub; Gabrielle J. Halpern; Nathan Ginott; Mordechai Shohat
Fragile-X syndrome is caused by an unstable CGG trinucleotide repeat in the FMR1 gene at Xq27. Intermediate alleles (51-200 repeats) can undergo expansion to the full mutation on transmission from mother to offspring. To evaluate the effectiveness of a fragile-X carrier-screening program, we tested 14,334 Israeli women of child-bearing age for fragile-X carrier status between 1992 and 2000. These women were either preconceptional or pregnant and had no family history of mental retardation. All those found to be carriers of premutation or full-mutation alleles were offered genetic counseling and also prenatal diagnosis, if applicable. We identified 207 carriers of an allele with >50 repeats, representing a prevalence of 1:69. There were 127 carriers with >54 repeats, representing a prevalence of 1:113. Three asymptomatic women carried the fully mutated allele. Among the premutation and full-mutation carriers, 177 prenatal diagnoses were performed. Expansion occurred in 30 fetuses, 5 of which had an expansion to the full mutation. On the basis of these results, the expected number of avoided patients born to women identified as carriers, the cost of the test in this study (U.S.
Genetics in Medicine | 2011
Mordechai Shohat; Gabrielle J. Halpern
100), and the cost of lifetime care for a mentally retarded person (>
European Journal of Human Genetics | 2007
Lina Basel-Vanagaite; Ellen Taub; Gabrielle J. Halpern; Valerie Drasinover; Nurit Magal; Bella Davidov; Joël Zlotogora; Mordechai Shohat
350,000), screening was calculated to be cost-effective. Because of the high prevalence of fragile-X premutation or full-mutation alleles, even in the general population, and because of the cost-effectiveness of the program, we recommend that screening to identify female carriers should be carried out on a wide scale.
International Journal of Biometeorology | 1995
Gabrielle J. Halpern; Eliahu Stoupel; Gad Barkai; R. Chaki; Cyril Legum; Moshe Fejgin; Mordechai Shohat
Familial Mediterranean fever is inherited in an autosomal recessive manner. There are two phenotypes: types 1 and 2. Familial Mediterranean fever type 1 is characterized by recurrent short episodes of inflammation and serositis, including fever, peritonitis, synovitis, pleuritis, and, rarely, pericarditis. The symptoms and severity vary among affected individuals, sometimes even among members of the same family. Amyloidosis, which can lead to renal failure, is the most severe complication. Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual. Routine treatment of end-stage renal disease, including renal transplantation, is advised. Lifelong treatment with colchicine is required for homozygotes for the p.Met694Val mutation or compound heterozygotes for p.Met694Val and another disease-causing allele; this prevents the inflammatory attacks and the deposition of amyloid. Individuals who do not have the p.Met694Val mutation and who are only mildly affected should be either treated with colchicine or monitored every 6 months for the presence of proteinuria. Molecular genetic testing of the MEFV gene, the only gene currently known to be associated with familial Mediterranean fever, can be offered to family members, especially when the p.Met694Val allele is present, because renal amyloidosis can be prevented by colchicine.
Public Health Genomics | 1998
Gerry Evers-Kiebooms; Lieve Denayer; Myriam Welkenhuysen; Mark F. Wildhagen; Theo A. van Os; Johan J. Polder; Leo P. ten Kate; J. Dik F. Habbema; Susan J. Hayflick; M. Patrice Eiff; Marleen Decruyenaere; Bernadette Modell; Anver Kuliev; Lutfi Jaber; Gabrielle J. Halpern; Mordechai Shohat; Neil A. Holtzman; Jörg Schmidtke
Nonsyndromic mental retardation (NSMR) is the diagnosis of exclusion in mentally retarded individuals without additional abnormalities. We have recently identified a protein-truncating mutation, G408fsX437, in the gene CC2D1A on chromosome 19p13.12 in nine consanguineous Israeli Arab families with severe autosomal recessive NSMR, and have developed a comprehensive prevention program among the at-risk population in the village. The subjects tested were healthy women who were invited to undergo the genetic screening test as a part of their routine pregnancy monitoring. One hundred and seventeen subjects reported a family history positive for mental retardation. We tested 524 pregnant or preconceptional women and found 47 carriers (∼1/11), whose spouses were then recommended to undergo testing. We identified eight carrier couples, who were given genetic counseling and offered prenatal diagnosis. Of all the marriages, 28.6% were consanguineous; 16.5% of the total were between first cousins. The high prevalence of the mutation can be explained both by the founder effect owing to the generally high consanguinity rate among the inhabitants of the village, and also because two families with excessive numbers of mentally retarded offspring were unacceptable as marriage partners by the rest of the families. This is the first example of the establishment of a large-scale genetic screening program for autosomal recessive NSMR, which was made possible owing to the high frequency of the specific causative mutation in this isolated population.
American Journal of Medical Genetics | 1997
Dov Inbar; Gabrielle J. Halpern; Raphael Weitz; Michelle Sadeh; Mordechai Shohat
We studied 2001 foetuses during the period of minimal solar activity of solar cycle 21 and 2265 foetuses during the period of maximal solar activity of solar cycle 22, in all women aged 37 years and over who underwent free prenatal diagnosis in four hospitals in the greater Tel Aviv area. There were no significant differences in the total incidence of chromosomal abnormalities or of trisomy between the two periods (2.15% and 1.8% versus 2.34% and 2.12%, respectively). However, the trend of excessive incidence of chromosomal abnormalities in the period of maximal solar activity suggests that a prospective study in a large population would be required to rule out any possible effect of extreme solar activity.
Pediatrics | 2000
Aviva Mimouni; Nurit Magal; Nava Stoffman; Tamy Shohat; Ara Minasian; Michael Krasnov; Gabrielle J. Halpern; Jerome I. Rotter; Nathan Fischel-Ghodsian; Yehuda L. Danon; Mordechai Shohat
This article is also accessible online at: http://BioMedNet.com/karger 1. Testing Laboratories, Equipment and Reagents All equipment and reagents for testing should be manufactured and maintained to an appropriate level and provide assured levels of accuracy and reliability that reflects current best practice. All laboratories offering genetic testing services should be appropriately staffed and equipped, and should: (1) participate in an appropriate accreditation scheme; (2) join an appropriate external quality assurance scheme, and (3) perform adequate internal quality control. All such systems should reflect current best practice.
Israel Medical Association Journal | 2000
Lutfi Jaber; Dolfin T; Shohat T; Gabrielle J. Halpern; Reish O; Fejgin M
Most reported familial cases of agenesis of the corpus callosum have followed either an autosomal recessive or an X-linked recessive pattern of inheritance. To the best of our knowledge, there is only one previous report of a family showing clear-cut autosomal dominant inheritance. We present the second such family, among whom a mother and her son had moderately severe coordination problems and low-normal intelligence. We suggest that agenesis of the corpus callosum, when transmitted as an autosomal dominant trait, is clinically characterized by a relatively milder phenotype than that occurring when inheritance is either autosomal or X-linked recessive and may be more common than has been thought.
American Journal of Otolaryngology | 1999
Mordechai Shohat; Nathan Fischel-Ghodsian; Cyril Legum; Gabrielle J. Halpern
Israel Medical Association Journal | 2004
Jalal Tarabeia; Yona Amitai; Manfred S. Green; Gabrielle J. Halpern; Sharon Blau; Anneke Ifrah; Naama Rotem; Lutfi Jaber